EcoDrugPlus

Vascular Endothelial Growth Factor A-A

Ensembl ID : ENSOKIG00005001653
Gene Symbol: LOC109864876
3 Cross references
175 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSOKIG00005007011
Gene Symbol: LOC109902230
2 Cross references
173 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSOKIG00005032185
Gene Symbol: LOC109900823
3 Cross references
195 Possible Orthologues:

Vasopressin V2 Receptor-Like

Ensembl ID : ENSOKIG00005042744
Gene Symbol: LOC109908323
2 Cross references
172 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSOKIG00005026962
Gene Symbol: VDR
1 Cross references
382 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSOKIG00005018692
Gene Symbol: VDR
1 Cross references
382 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSOKIG00005018812
Gene Symbol: LOC109867661
3 Cross references
385 Possible Orthologues:

Vitamin D3 Receptor B-Like

Ensembl ID : ENSOKIG00005034417
Gene Symbol: LOC116374233
3 Cross references
386 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSOKIG00005030782
Gene Symbol: LOC109888802
3 Cross references
190 Possible Orthologues:

Vitamin K-Dependent Protein Z

Ensembl ID : ENSOKIG00005036165
Gene Symbol: LOC109887405
2 Cross references
235 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-1

Ensembl ID : ENSOKIG00005019697
Gene Symbol: LOC109893290
3 Cross references
203 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-1-Like

Ensembl ID : ENSOKIG00005033925
Gene Symbol: LOC109898387
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).